Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18383395rdf:typepubmed:Citationlld:pubmed
pubmed-article:18383395lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18383395lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18383395lifeskim:mentionsumls-concept:C0039263lld:lifeskim
pubmed-article:18383395lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:18383395lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:18383395pubmed:issue4lld:pubmed
pubmed-article:18383395pubmed:dateCreated2008-4-22lld:pubmed
pubmed-article:18383395pubmed:abstractTextTakayasu arteritis (TA) is a chronic inflammatory disease that involves the aorta and its major branches. Since overproduction of interleukin-6 (IL-6) seems to play a pathogenic role in TA, we used the anti-IL-6 receptor (IL-6R) antibody tocilizumab to treat a 20-year-old woman with refractory active TA complicated by ulcerative colitis (UC). Treatment with tocilizumab improved the clinical manifestations of TA and the abnormal laboratory findings in this patient and ameliorated the activity of UC. These results indicate that IL-6R inhibition with tocilizumab might be a future treatment option for TA.lld:pubmed
pubmed-article:18383395pubmed:languageenglld:pubmed
pubmed-article:18383395pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18383395pubmed:citationSubsetAIMlld:pubmed
pubmed-article:18383395pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18383395pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18383395pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18383395pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18383395pubmed:statusMEDLINElld:pubmed
pubmed-article:18383395pubmed:monthAprlld:pubmed
pubmed-article:18383395pubmed:issn0004-3591lld:pubmed
pubmed-article:18383395pubmed:authorpubmed-author:MimaToruTlld:pubmed
pubmed-article:18383395pubmed:authorpubmed-author:NishimotoNori...lld:pubmed
pubmed-article:18383395pubmed:authorpubmed-author:NakaharaHidek...lld:pubmed
pubmed-article:18383395pubmed:authorpubmed-author:Yoshio-Hoshin...lld:pubmed
pubmed-article:18383395pubmed:issnTypePrintlld:pubmed
pubmed-article:18383395pubmed:volume58lld:pubmed
pubmed-article:18383395pubmed:ownerNLMlld:pubmed
pubmed-article:18383395pubmed:authorsCompleteYlld:pubmed
pubmed-article:18383395pubmed:pagination1197-200lld:pubmed
pubmed-article:18383395pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:18383395pubmed:meshHeadingpubmed-meshheading:18383395...lld:pubmed
pubmed-article:18383395pubmed:meshHeadingpubmed-meshheading:18383395...lld:pubmed
pubmed-article:18383395pubmed:meshHeadingpubmed-meshheading:18383395...lld:pubmed
pubmed-article:18383395pubmed:meshHeadingpubmed-meshheading:18383395...lld:pubmed
pubmed-article:18383395pubmed:meshHeadingpubmed-meshheading:18383395...lld:pubmed
pubmed-article:18383395pubmed:meshHeadingpubmed-meshheading:18383395...lld:pubmed
pubmed-article:18383395pubmed:meshHeadingpubmed-meshheading:18383395...lld:pubmed
pubmed-article:18383395pubmed:year2008lld:pubmed
pubmed-article:18383395pubmed:articleTitleSuccessful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.lld:pubmed
pubmed-article:18383395pubmed:affiliationLaboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, Osaka, Japan. norihiro@fbs.osaka-u.ac.jplld:pubmed
pubmed-article:18383395pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18383395pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:18383395pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18383395lld:pubmed